Valeo Pharma Inc. news

• Hesperco now available in approximately 300 stores under the Loblaws banners
• Clinical study yields encouraging results that hesperidin may help reduce COVID-19 associated symptoms

Valeo Pharma Inc. (CSE:VPH, OTCQB:VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company,

• Public reimbursement now includes Alberta, Quebec and Nova Scotia, representing approximately 37% of the Canadian population.
  More than 90% private insurance coverage across Canada

Valeo Pharma Inc. (CSE:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, is proud to announce a major milestone for its two inn

• Public reimbursement coverage reaches 9 Provinces in Canada
• Canadian private health plan coverage now exceeding 90%

Valeo Pharma Inc. (CSE:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that it has successfully entered into a Product Listing Agreement (“PLA”)

• First provincial public listing secured for both asthma medications 
• Additional provincial public reimbursement coverage expected to follow soon
  
• 85% private payer health plan coverage across Canada

Valeo Pharma Inc. (CSE:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceu